CUDC-101

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCUDC-101
Drug Alias NameCUDC-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitorsEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Histone deacetylase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsLiver Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCuris Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCuris Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsLiver Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A